Analysts Set DexCom, Inc. (NASDAQ:DXCM) PT at $111.63

Shares of DexCom, Inc. (NASDAQ:DXCM) have been assigned a consensus rating of “Moderate Buy” from the eighteen brokerages that are currently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a hold recommendation, eleven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have covered the stock in the last year is $111.63.

DXCM has been the subject of several research analyst reports. Baird R W cut DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Raymond James raised their price objective on shares of DexCom from $151.00 to $160.00 and gave the company a “strong-buy” rating in a research note on Friday, April 26th. Wells Fargo & Company lowered their target price on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. BTIG Research reduced their price target on shares of DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, July 26th. Finally, Piper Sandler lowered their price target on DexCom from $150.00 to $90.00 and set an “overweight” rating on the stock in a report on Friday, July 26th.

Insiders Place Their Bets

In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the sale, the executive vice president now owns 66,249 shares in the company, valued at $4,607,617.95. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Michael Jon Brown sold 652 shares of the stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $69.55, for a total transaction of $45,346.60. Following the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Bridgette P. Heller sold 1,000 shares of DexCom stock in a transaction dated Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the completion of the sale, the director now owns 25,349 shares of the company’s stock, valued at approximately $2,878,378.95. The disclosure for this sale can be found here. In the last three months, insiders sold 4,135 shares of company stock valued at $446,797. Company insiders own 0.30% of the company’s stock.

Hedge Funds Weigh In On DexCom

A number of hedge funds have recently made changes to their positions in DXCM. NewEdge Advisors LLC boosted its holdings in DexCom by 18.3% in the second quarter. NewEdge Advisors LLC now owns 9,020 shares of the medical device company’s stock valued at $1,023,000 after acquiring an additional 1,393 shares during the last quarter. Creative Planning grew its holdings in shares of DexCom by 4.9% during the 2nd quarter. Creative Planning now owns 48,693 shares of the medical device company’s stock worth $5,521,000 after purchasing an additional 2,271 shares during the period. Magnolia Capital Advisors LLC acquired a new stake in DexCom during the 2nd quarter worth approximately $731,000. Ascent Group LLC raised its holdings in DexCom by 17.0% in the second quarter. Ascent Group LLC now owns 7,367 shares of the medical device company’s stock valued at $835,000 after buying an additional 1,072 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in DexCom during the second quarter valued at approximately $3,728,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Stock Up 3.2 %

Shares of NASDAQ:DXCM opened at $74.65 on Friday. DexCom has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a quick ratio of 2.48, a current ratio of 2.82 and a debt-to-equity ratio of 1.00. The firm’s 50-day simple moving average is $99.67 and its 200-day simple moving average is $118.03. The company has a market cap of $29.69 billion, a price-to-earnings ratio of 48.16, a PEG ratio of 2.18 and a beta of 1.16.

DexCom (NASDAQ:DXCM) last announced its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue was up 15.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.34 earnings per share. As a group, equities research analysts predict that DexCom will post 1.69 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.